Clinical trial
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of…
NCT00442325 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00442325 |
|---|---|
| Title | Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets |
| Official title | ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With… |
| Acronym | ACTFAST 2 |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia, Peripheral Vascular Disease |
| Intervention type | Drug |
| Interventions | Atorvastatin (Lipitor) |
| Enrollment | 595 |
| Start date | Jan 1, 2003 |
| Completion | Feb 1, 2004 |
| First posted | Mar 1, 2007 |
| Last update posted | Feb 18, 2021 |
| Countries | Greece, Hungary, Ireland, Poland, Portugal, Russia, Slovakia, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: